These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 9680143)
21. Immunogenic properties of the small chain HA2 of the haemagglutinin of influenza viruses. Becht H; Huang RT; Fleischer B; Boschek CB; Rott R J Gen Virol; 1984 Jan; 65 ( Pt 1)():173-83. PubMed ID: 6363620 [TBL] [Abstract][Full Text] [Related]
22. Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human. Yamayoshi S; Ito M; Uraki R; Sasaki T; Ikuta K; Kawaoka Y J Infect; 2018 Feb; 76(2):177-185. PubMed ID: 29248585 [TBL] [Abstract][Full Text] [Related]
23. The strong positive correlation between effective affinity and infectivity neutralization of highly cross-reactive monoclonal antibody IIB4, which recognizes antigenic site B on influenza A virus haemagglutinin. Kostolanský F; Varecková E; Betáková T; Mucha V; Russ G; Wharton SA J Gen Virol; 2000 Jul; 81(Pt 7):1727-35. PubMed ID: 10859378 [TBL] [Abstract][Full Text] [Related]
24. Molecular and immunological characterization of soluble aggregated A/Victoria/3/75 (H3N2) influenza haemagglutinin expressed in insect cells. Vanlandschoot P; Beirnaert E; Neirynck S; Saelens X; Jou WM; Fiers W Arch Virol; 1996; 141(9):1715-26. PubMed ID: 8893793 [TBL] [Abstract][Full Text] [Related]
25. Development of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009) using plasmid DNA immunogen. Cabral TM; Baig A; Berhane Y; Schmidt L; Hole K; Leith M; Kobasa D; Corbett CR J Virol Methods; 2014 Jan; 195():54-62. PubMed ID: 24060631 [TBL] [Abstract][Full Text] [Related]
26. Development and characterization of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009). Cabral TM; Berhane Y; Schmidt L; Tracz DM; Hole K; Leith M; Corbett CR J Virol Methods; 2012 Jul; 183(1):25-33. PubMed ID: 22575685 [TBL] [Abstract][Full Text] [Related]
27. Interference with a conformational change in the haemagglutinin molecule of influenza virus by antibodies as a possible neutralization mechanism. Kida H; Yoden S; Kuwabara M; Yanagawa R Vaccine; 1985 Sep; 3(3 Suppl):219-22. PubMed ID: 4060852 [TBL] [Abstract][Full Text] [Related]
29. Fab MAbs specific to HA of influenza virus with H5N1 neutralizing activity selected from immunized chicken phage library. Pitaksajjakul P; Lekcharoensuk P; Upragarin N; Barbas CF; Ibrahim MS; Ikuta K; Ramasoota P Biochem Biophys Res Commun; 2010 May; 395(4):496-501. PubMed ID: 20382115 [TBL] [Abstract][Full Text] [Related]
30. Relating influenza virus membrane fusion kinetics to stoichiometry of neutralizing antibodies at the single-particle level. Otterstrom JJ; Brandenburg B; Koldijk MH; Juraszek J; Tang C; Mashaghi S; Kwaks T; Goudsmit J; Vogels R; Friesen RH; van Oijen AM Proc Natl Acad Sci U S A; 2014 Dec; 111(48):E5143-8. PubMed ID: 25404330 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of influenza virus haemolytic and haemagglutination activities by monoclonal antibodies to haemagglutinin glycopolypeptides HA1 and HA2. Kostolanský F; Styk B; Russ G Acta Virol; 1989 Dec; 33(6):504-12. PubMed ID: 2576592 [TBL] [Abstract][Full Text] [Related]
32. A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus. Wu Y; Cho M; Shore D; Song M; Choi J; Jiang T; Deng YQ; Bourgeois M; Almli L; Yang H; Chen LM; Shi Y; Qi J; Li A; Yi KS; Chang M; Bae JS; Lee H; Shin J; Stevens J; Hong S; Qin CF; Gao GF; Chang SJ; Donis RO Nat Commun; 2015 Jul; 6():7708. PubMed ID: 26196962 [TBL] [Abstract][Full Text] [Related]
33. Intermediates in influenza virus PR/8 haemagglutinin-induced membrane fusion. Pak CC; Krumbiegel M; Blumenthal R J Gen Virol; 1994 Feb; 75 ( Pt 2)():395-9. PubMed ID: 8113761 [TBL] [Abstract][Full Text] [Related]
34. Studies on the structure of the influenza virus haemagglutinin at the pH of membrane fusion. Ruigrok RW; Aitken A; Calder LJ; Martin SR; Skehel JJ; Wharton SA; Weis W; Wiley DC J Gen Virol; 1988 Nov; 69 ( Pt 11)():2785-95. PubMed ID: 3183628 [TBL] [Abstract][Full Text] [Related]
35. Mechanism of neutralization of influenza virus infectivity by antibodies. Knossow M; Gaudier M; Douglas A; Barrère B; Bizebard T; Barbey C; Gigant B; Skehel JJ Virology; 2002 Oct; 302(2):294-8. PubMed ID: 12441073 [TBL] [Abstract][Full Text] [Related]
36. High and low efficiency neutralization epitopes on the haemagglutinin of type A influenza virus. Schofield DJ; Stephenson JR; Dimmock NJ J Gen Virol; 1997 Oct; 78 ( Pt 10)():2441-6. PubMed ID: 9349462 [TBL] [Abstract][Full Text] [Related]
37. The specific inhibition of influenza A virus maturation by amantadine: an electron microscopic examination. Ruigrok RW; Hirst EM; Hay AJ J Gen Virol; 1991 Jan; 72 ( Pt 1)():191-4. PubMed ID: 1990063 [TBL] [Abstract][Full Text] [Related]
38. Characterization of antibody and cytotoxic T lymphocyte responses to human influenza virus H3 haemagglutinin expressed from the haemagglutinin locus of vaccinia virus. Itamura S; Iinuma H; Shida H; Morikawa Y; Nerome K; Oya A J Gen Virol; 1990 Dec; 71 ( Pt 12)():2859-65. PubMed ID: 2273387 [TBL] [Abstract][Full Text] [Related]
39. Identification of a linear epitope on the haemagglutinin protein of pandemic A/H1N1 2009 influenza virus using monoclonal antibodies. Chen Y; Zhang J; Qiao C; Wang J; Yang H; Chen H Arch Virol; 2014 Jun; 159(6):1413-9. PubMed ID: 24385157 [TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibodies to influenza A virus FM1 (H1N1) proteins require individual conditions for optimal reactivity in binding assays. Kammer K Immunology; 1983 Apr; 48(4):799-808. PubMed ID: 6187672 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]